2016
DOI: 10.1111/hepr.12758
|View full text |Cite
|
Sign up to set email alerts
|

Non‐response to daclatasvir and asunaprevir therapy in patients co‐infected with hepatitis C virus genotypes 1 and 2

Abstract: Direct-acting antiviral agents for hepatitis C virus (HCV) have been developed such as combined daclatasvir (DCV) and asunaprevir (ASV) treatment. This typically enables HCV serotype 1 patients to achieve a high sustained virological response rate, but a small number of such patients fail to respond to therapy. We investigated three HCV patients who showed no response to DCV and ASV therapy. Hepatitis C genotyping was undertaken in the three patients using nested polymerase chain reaction and polymerase chain … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
6
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 18 publications
0
6
0
Order By: Relevance
“…Regretfully, serum samples before DCV/ASV therapy could not be obtained from Patient 2-4. Therefore, it is not completely denied that they had co-infection of HCV of genotype 1b and other genotypes as reported recently from Japan (Sohda et al 2016), and that only genotype 1b HCV was cleared after DCV/ASV treatment. Also, there is another possibility that the patients were infected transiently with genotype 1 HCV and had acquired antibodies against the virus.…”
Section: Discussionmentioning
confidence: 91%
“…Regretfully, serum samples before DCV/ASV therapy could not be obtained from Patient 2-4. Therefore, it is not completely denied that they had co-infection of HCV of genotype 1b and other genotypes as reported recently from Japan (Sohda et al 2016), and that only genotype 1b HCV was cleared after DCV/ASV treatment. Also, there is another possibility that the patients were infected transiently with genotype 1 HCV and had acquired antibodies against the virus.…”
Section: Discussionmentioning
confidence: 91%
“…Undiagnosed mixed genotype would result in treatment failure, but the impact of mixed genotype on SVR in real-world experience remains unclear. On the basis of this clinical speculation, Sohda et al [12] found 3 mixed types in a nonresponder to DCV and ASV therapy and postulated that mixed genotype caused nonresponse to genotype-specific DAA therapy. In our study, none of the patients with mixed infection received the DCV and ASV or LDV/SOF regimen; but 2 patients received SOF plus RBV.…”
Section: Discussionmentioning
confidence: 99%
“…2 had been a candidate for sofosbuvir and ribavirin regimen based on the serotyping results (serotype 2), but the patient was treated with daclatasvir and asunaprevir regimen after getting the genotyping result of genotype 1b and achieved SVR24. Sohda et al [ 28 ] reported the non-response to daclatasvir and asunaprevir therapy in patients coinfected with hepatitis C virus genotypes 1 and 2.…”
Section: Discussionmentioning
confidence: 99%